Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

argenx Announces Plan To Continue The Development Of Efgartigimod Primary Sjogren's Disease

Author: Benzinga Newsdesk | March 27, 2024 03:06am

RHO study supports proof-of-concept in primary Sjogren's disease
Decision informed by favorable safety profile and consistency across efficacy and biomarker measures

Posted In: ARGX